Drug Profile
Azelastine/budesonide intranasal - Sedor
Alternative Names: Captisol-enabled™ Budesonide + Azelastine nasal spray - Sedor; CDX-313; LGD-313Latest Information Update: 04 Oct 2017
Price :
$50
*
At a glance
- Originator CyDex Pharmaceuticals
- Developer Sedor Pharmaceuticals
- Class Glucocorticoids; Phthalazines; Pregnenediones; Small molecules
- Mechanism of Action Glucocorticoid receptor agonists; Histamine H1 receptor antagonists; Mast cell stabilisers
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase II Seasonal allergic rhinitis
Most Recent Events
- 04 Oct 2017 Azelastine/budesonide is still at phase II development stage for Seasonal allergic rhinitis in Canada (Intranasal) (Sedor Pharmaceuticals website, October 2017)
- 08 Dec 2015 Captisol-enabled™ azelastine/budesonide licensed to RODES Pharmaceuticals in USA
- 08 Dec 2015 RODES plans a phase I trial for Seasonal allergic rhinitis in USA (Intranasal)